explore -WSS

explore

author：fashion 2025-10-01 05:38:12 - browse：4681

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

focus

WSS

340B reform proposal comes out of Senate working group

Devoted Health’s losses in Medicare Advantage persist

Readout LOUD: Venture capital, Gilead, and more M&A

Startup Neumora takes a novel depression drug to Phase 3

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Biden tests positive for Covid

focus

explore

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden tests positive for Covid

Virginia high school admissions case could be legal follow

Texas Medical Board asked to define abortion emergency exception

Sports medicine is finally prioritizing gender equality

Biden tests positive for Covid

In Memoriam: Notable people who died in 2023

Readout Newsletter: Amgen, Regeneron, BGI Group and more

In Memoriam: Notable people who died in 2023

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

entertainment

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Biden tests positive for Covid

Google and Epic fight stronger regulation of AI in health care

Listen: Wegovy in the brain & pivotal Alzheimer's data

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

AI gets buy

focus

knowledge

focus

explore